The evolution in clinical care is expected to offer a brand new stage of diagnosing, cancer treatments for each specific individual
FARMINGTON, Conn., Aug. 16, 2012 /PRNewswire-iReach/ -- "Personalized" cancer care has never had it better, and three drugs have been responsible for confirming their prospects to combat certain common cancers. Of these, two studies have focused on drugs for treating advanced melanoma, and a third study has explored a gene-targeted chemotherapy for a subset of lung cancers. All the three drugs have proved their efficacy in Phase III trials, and tailored medications similar to these are being used in metastasis or cancer settings. Advanced lung cancer and advanced melanoma necessitate targeted therapies that form the standard of care.
The past scenario involved doctors administering cancer drugs to patients as a normal course, in the anticipation that response levels in at least some of the patients would be positive. However, with the advent of personalized medicine, this method has taken a back seat, and greater emphasis is being given to patient-centric approaches for targeting therapies towards genetic abnormalities in cancers that are responsible for driving cancer growth.
Global Information, Inc. presents the latest analysis market research published by Industry Experts and the upcoming ADAPT 2012 in Washington, DC.
Market Research: Personalized Medicine - A Global Market Overview
Personalized Medicine product segments analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Molecular Diagnostics and Self/Other Diagnostics.
Biologics have gained prominence in treating systemic and cutaneous autoimmune diseases, with a design that targets particular components of immune system. Since novel drugs can target proteins in a more precise manner, in addition to having reduced risks of systemic side effects, they offer significant benefits as compared to the erstwhile immunomodulators. For instance, crucial advances have been achieved in developing TNF-alpha blockers for treating psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease and ankylosing spondylitis in the same manner, B-cell depletion has revolutionized treatment of lupus, pemphigus, certain vasculitides, etc. Having said this, development of these molecules and their clinical usage are as yet in the evolutionary process.
Further categorization of patients' clinical profiles requiring the use of biologics has to reach a culmination point due to the fact that the long-term safety profiles of such agents are largely hidden at present.
Pharmacogenomics is the branch of pharmacology dealing with the influence of genetic variation on drug response in patients through the correlation of gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. This is focused towards developing rational means for optimizing drug therapy relating to the patients' genotype, ensuring maximum efficacy with minimal adverse effects. Pharmacogenomics offers the prospect of advancing personalized medicine to levels where drugs and drug combinations can be optimized for every individual's unique genetic makeup. Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs.
An Executive Summary of this analysis, full table of contents, and a free sample/whitepaper of the full report are available at http://www.giiresearch.com/report/inde248627-personalized-medicine-global-market-overview.html
Industry Event in Washington, DC 9/19-21, 2012
Cambridge Healthtech Institute is pleased to announce the Fourth Annual ADAPT 2012: Accelerating Development & Advancing Personalized Therapy Congress, which will be held at the Renaissance Washington, DC Downtown Hotel in Washington, DC, September 19-21, 2012. This year, the coverage has been expanded to seven concurrent tracks, focusing on (1) strategies to accelerate and de-risk drug and diagnostic development through innovative clinical programs and utilizing biomarker data in decision making; (2) implementing personalized medicine though drug-diagnostic co-development; and (3) innovative non-invasive diagnostics for cancer and other diseases. ADAPT 2012 attracts a balanced mix of delegates from pharma and diagnostic companies, clinical organizations, academia, and government, providing a unique opportunity to learn from the thought leaders, network with the decision makers, and discover actionable implementation strategies bridging drug and diagnostic development.
View all details http://www.giiconference.com/chi229586-2012/
Register today https://www.giiresearch.com/conference/en/order/229586
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Jeremy Palaia Global Information, Inc., 860-674-8796, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.